Iron homeostasis in the Metabolic Syndrome

European Journal of Clinical Investigation

Volumn 43, Issue 2, 2013, Pages 215-224

  Datz, Christian ^a   Felder, Thomas K ^b   Niederseer, David ^a   Aigner, Elmar ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

FPN ferroportin 1; Hepcidin; Iron overload; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

CERULOPLASMIN; COPPER; DEFEROXAMINE; FERRITIN; FERROPORTIN; GLUCOSE; HEMOGLOBIN A1C; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXO; TRANSFERRIN RECEPTOR;

BLOOD PRESSURE; BODY MASS; CERULOPLASMIN BLOOD LEVEL; DISEASE COURSE; DYSMETABOLIC IRON OVERLOAD SYNDROME; ERYTHROPHAGOCYTOSIS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERFERRITINEMIA; INSULIN SENSITIVITY; IRON ABSORPTION; IRON DEFICIENCY; IRON OVERLOAD; IRON STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CATION TRANSPORT PROTEINS; FATTY LIVER; HOMEOSTASIS; HUMANS; IRON; IRON OVERLOAD; METABOLIC SYNDROME X; OBESITY;

EID: 84872613270     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12032     Document Type: Review

References (72)

1. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117:285-97.
2. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-63.
3. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309.
4. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999;21:195-9.
5. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-12.
6. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Investig 2002;110:1037-44.
7. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (New York, N.Y) 2004;306:2090-3.
8. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006;131:788-96.
9. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
10. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003;361:669-73.
11. Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005;105:376-81.
12. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology (Baltimore, Md) 2007;46:1291-301.
13. Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science (New York, N.Y) 2008;320:1088-92.
14. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-71.
15. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-6.
16. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001;116:263-70.
17. Guillygomarc'h A, Mendler MH, Moirand R, Laine F, Quentin V, David V, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001;35:344-9.
18. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
19. Wood RJ. The iron-heart disease connection: is it dead or just hiding? Ageing Res Rev 2004;3:355-67.
20. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999;22:1978-83.
21. Lao TT, Chan PL, Tam KF. Gestational diabetes mellitus in the last trimester - a feature of maternal iron excess? Diabet Med 2001;18:218-23.
22. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-17.
23. Iwasaki T, Nakajima A, Yoneda M, Yamada Y, Mukasa K, Fujita K, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005;28:2486-91.
24. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005;51:1201-5.
25. Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006;154:333-40.
26. Galan P, Noisette N, Estaquio C, Czernichow S, Mennen L, Renversez JC, et al. Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Mineraux AntioXydants) cohort. Public Health Nutr 2006;9:70-4.
27. Dubern B, Girardet JP, Tounian P. Insulin resistance and ferritin as major determinants of abnormal serum aminotransferase in severely obese children. Int J Pediatr Obes 2006;1:77-82.
28. Aigner E, Hinz C, Steiner K, Rossmann B, Pfleger J, Hohla F, et al. Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. Eur J Clin Invest 2010;40:155-63.
29. Ramakrishnan U, Kuklina E, Stein AD. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 2002;76:1256-60.
30. Martinez-Garcia MA, Luque-Ramirez M, San-Millan JL, Escobar-Morreale HF. Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. Diabetes Care 2009;32:1525-30.
31. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL, Escobar-Morreale HF. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007;30:2309-13.
32. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-55.
33. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-18.
34. Fierbinteanu-Braticevici C, Bengus A, Neamtu M, Usvat R. The risk factors of fibrosis in nonalcoholic steatohepatitis. Rom J Intern Med 2002;40:81-8.
35. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, et al. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003;35:172-8.
36. Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (Baltimore, MD) 2002;36:142-9.
37. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (Baltimore, MD) 2004;39:179-87.
38. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
39. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2012;55:77-85.
40. Weismuller TJ, Kirchner GI, Scherer MN, Negm AA, Schnitzbauer AA, Lehner F, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology (Baltimore, MD) 2011;54:2114-24.
41. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (Baltimore, MD) 2010;51:1683-91.
42. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009;50:351-7.
43. Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WH. Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2011;55:1079-85.
44. Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2010;53:927-33.
45. Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology (Baltimore, MD) 2012;56:1730-40.
46. Abraham D, Rogers J, Gault P, Kushner JP, McClain DA. Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia 2006;49:2546-51.
47. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig 2004;114:1752-61.
48. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008;172:738-47.
49. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 2006;55:1042-5.
50. Ku BJ, Kim SY, Lee TY, Park KS. Serum ferritin is inversely correlated with serum adiponectin level: population-based cross-sectional study. Dis Markers 2009;27:303-10.
51. Fernandez-Real JM, Moreno JM, Ricart W. Circulating RBP4 concentration might reflect insulin resistance-associated iron overload. Diabetes 2008;57:1918-25.
52. Fernandez-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 2007;30:616-21.
53. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55:920-32.
54. Chung B, Matak P, McKie AT, Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr 2007;137:2366-70.
55. Cheng HL, Bryant C, Cook R, O'Connor H, Rooney K, Steinbeck K. The relationship between obesity and hypoferraemia in adults: a systematic review. Obes Rev 2012;13:150-61.
56. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, et al. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol 2008;49:123-33.
57. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008;87:1374-83.
58. Dallalio G, Law E, Means RT, Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2702-4.
59. Aigner E, Felder TK, Oberkofler H, Hahne P, Auer S, Soyal S et al. Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem 2013;24:112-7.
60. Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008;135:680-8.
61. Ruivard M, Laine F, Ganz T, Olbina G, Westerman M, Nemeth E, et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009;50:1219-25.
62. Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007;170:967-80.
63. Yokomori N, Iwasa Y, Aida K, Inoue M, Tawata M, Onaya T. Transcriptional regulation of ferritin messenger ribonucleic acid levels by insulin in cultured rat glioma cells. Endocrinology 1991;128:1474-80.
64. De Domenico I, Ward DM, di Patti MC, Jeong SY, David S, Musci G, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007;26:2823-31.
65. Piperno A, Vergani A, Salvioni A, Trombini P, Vigano M, Riva A, et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004;24:471-6.
66. Facchini FS. Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998;21:2190.
67. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF et al., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-804.
68. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003;124:866; author reply -7.
69. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002;51:1000-4.
70. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-8.
71. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
72. Beaton MD, Adams PC. Treatment of hyperferritinemia. Ann Hepatol 2012;11:294-300.